1. Home
  2. ASC vs ERAS Comparison

ASC vs ERAS Comparison

Compare ASC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardmore Shipping Corporation

ASC

Ardmore Shipping Corporation

HOLD

Current Price

$18.67

Market Cap

751.7M

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$16.04

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASC
ERAS
Founded
2010
2018
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
751.7M
6.3B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ASC
ERAS
Price
$18.67
$16.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
12
Target Price
$17.00
$14.25
AVG Volume (30 Days)
564.8K
3.4M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
1.74%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.31
$1.53
52 Week High
$20.03
$24.28

Technical Indicators

Market Signals
Indicator
ASC
ERAS
Relative Strength Index (RSI) 59.73 38.62
Support Level $18.14 $12.36
Resistance Level $18.91 $19.13
Average True Range (ATR) 0.61 1.29
MACD 0.01 -0.25
Stochastic Oscillator 78.48 10.30

Price Performance

Historical Comparison
ASC
ERAS

About ASC Ardmore Shipping Corporation

Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: